Surzebiclimab

Generic Name: Surzebiclimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2342597-90-2

Unique Ingredient Identifier: 53YMC3A1CU

Background: Surzebiclimab is under investigation in clinical trial NCT03744468 (Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3

Conditions: Advanced Malignancies

Interventions: Drug: Tislelizumab
Drug: Pamiparib
Drug: Sitravatinib
Drug: BGB-15025
Drug: Zanidatamab
Drug: Temozolomide
Drug: Ociperlimab
Drug: BAT1706
Drug: Fruquintinib
Drug: BGB-A445
Drug: Surzebiclimab
Drug: Lenvatinib
Drug: LBL-007

First Posted Date: 2019-11-15

Last Posted Date: 2024-12-16

Lead Sponsor: BeiGene

Target Recruit Count: 300

Registration Number: NCT04164199

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China

and more 70 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy